Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML

被引：0

作者：

Millot, Frederic ^{[1
]}

De Keizer, Joe ^{[2
]}

Metzler, Markus ^{[3
]}

Suttorp, Meinolf ^{[4
]}

Sedlacek, Petr ^{[5
]}

Luesink, Maaike ^{[6
]}

Cheng, Frankie W. T. ^{[7
]}

Kalwak, Krzysztof ^{[8
,9
]}

Lausen, Birgitte ^{[10
]}

Jakovljevic, Gordana ^{[11
]}

De Moerloose, Barbara ^{[12
]}

Dworzak, Michael ^{[13
]}

Borisevich, Marina ^{[14
]}

Yajima, Julia ^{[15
]}

Ampatzidou, Mirella ^{[16
]}

Farah, Roula ^{[17
]}

Kaiserova, Emilia ^{[18
]}

Guenes, Adalet Meral ^{[19
]}

Baruchel, Andre ^{[20
]}

机构：

[1] CHU Poitiers, Inserm, CIC 1402, Poitiers, France

[2] Inserm, CIC 1402, Poitiers, France

[3] Univ Hosp Erlangen, Dept Pediat & Adolescent Med, Erlangen, Germany

[4] Tech Univ, Fac Med, Pediat Hematol & Oncol, Dresden, Germany

[5] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic

[6] Princess Maxima Ctr Pediat Oncol, Dutch Childhood Oncol Grp, Utrecht, Netherlands

[7] Prince Wales Hosp, Dept Pediat, Hong Kong, Peoples R China

[8] Wroclaw Med Univ, Dept Pediat Hematol Oncol, Wroclaw, Poland

[9] Wroclaw Med Univ, BMT, Wroclaw, Poland

[10] Univ Copenhagen, Dept Pediat & Adolescent Med, Rigshosp, Copenhagen, Denmark

[11] Childrens Hosp, Dept Pediat Hematol Oncol, Zagreb, Croatia

[12] Ghent Univ Hosp, Dept Pediat Hematol Oncol, Ghent, Belgium

[13] St Anna Childrens Canc Res Inst, Vienna, Austria

[14] Belarusian Res Ctr Pediat Oncol Hematol & Immunol, Minsk, BELARUS

[15] Ctr Infantil Boldrini, Sao Paulo, Brazil

[16] Aghia Sophia Childrens Hosp, Dept Pediat Hematol Oncol, Athens, Greece

[17] LAU Med Ctr Rizk Hosp, Dept Pediat, Beirut, Lebanon

[18] Univ Childrens Hosp, Dept Pediat Oncol, Bratislava, Slovakia

[19] Hosp Gorukle, Pediat Hematol & Oncol, Bursa, Turkiye

[20] Robert Debre Hosp, Dept Pediat Hematol, Paris, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173810

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

下载

页数：4

共 50 条

[21] Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study)
Millot, Frederic
Guilhot, Joelle
Suttorp, Meinolf
Meunier, Anne Sophie
Meral, Gunes Adalet
Sedlacek, Petr
de Bont, Eveline
Li, Chi Kong
Kalwak, Krzysztof
Lausen, Birgitte
Culic, Srdjana
De Moerloose, Barbara
Biondi, Andrea
Baruchel, Andre
BLOOD, 2015, 126 (23)
[22] EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC)
Nazha, Aziz
Jabbour, Elias
Cortes, Jorge E.
O'Brien, Susan
Shan, Jenny
Garcia-Manero, Guillermo
Quintas-Cardama, Alfonso
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 1609 - 1609
[23] Long-term 5-year results of the phase 3 DASISION trial (dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase [CML-CP])
Stegelmann, F.
Cortes, J.
Saglio, G.
Baccarani, M.
Kantarjian, H.
Mayeri, J.
Bogue, C.
Shah, N. P.
Chuah, C.
Casanova, L.
Narayanan, G.
Bradley-Garelik, B.
Manos, G.
Hochhaus, A.
Oncology Research and Treatment, 2015, 38 : 23 - 24
[24] EPIC: A PHASE 3 TRIAL OF PONATINIB VS IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CP-CML)
Chuah, C.
Guerci-Bresler, A.
Rosti, G.
Simpson, D.
Lustgarten, S.
Trede, N.
Rivera, V. M.
Clackson, T.
Haluska, F. G.
Baccarani, M.
Cortes, J. E.
Guilhot, F.
Hochhaus, A.
Hughes, T.
Kantarjian, H.
Shah, N. P.
Talpaz, M.
Deininger, M. W.
Lipton, J. H.
HAEMATOLOGICA, 2014, 99 : 238 - 238
[25] ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
Hughes, Timothy P.
Hochhaus, Andreas
Saglio, Giuseppe
Kim, Dong-Wook
Jootar, Saengsuree
le Coutre, Philipp D.
Reiffers, Josy
Pasquini, Ricardo
Lobo, Clarisse
Clark, Richard E.
Gallagher, Neil J.
Hoenekopp, Albert
Haque, Ariful
Larson, Richard A.
Kantarjian, Hagop M.
BLOOD, 2010, 116 (21) : 94 - 95
[26] Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update
Mauro, Michael J.
Dakhil, Shaker
Cortes, Jorge E.
Rizzieri, David A.
Keir, Christopher H.
Yi, Sandy
Heinrich, Michael C.
Goldberg, Stuart L.
Catchatourian, Rosalind
Kuriakose, Philip
Radich, Jerald P.
BLOOD, 2014, 124 (21)
[27] Imatinib in children with newly diagnosed chronic phase chronic myelogenous leukemia (CP CML): AAML0123 COG study.
Champagne, Martin A.
Fu, Cecilia
Chang, Myron
Cooley, Linda
Heerema, Nyla A.
Wood, Charlotte
French, Mary Ellen
Smith, Franklin O.
Bernstein, Mark L.
BLOOD, 2006, 108 (11) : 607A - 607A
[28] Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis
Stegelmann, F.
Mayer, J.
Warzocha, K.
Huguet, F.
Steegmann, J. L.
Gambacorti-Passerini, C.
Lofgren, C.
Dejardin, D.
Hochhaus, A.
ONKOLOGIE, 2012, 35 : 47 - 48
[29] Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in long-term outcome for patients (Pts) with chronic phase (CP) chronic myeloid leukemia (CML)
Alvarado, Yesid
Kantarjian, Hagop
Faderl, Stefan
Burger, Jan
Borthakur, Gautam
O'Brien, Susan
Wierda, William
Garcia-Manero, Guillermo
Cortes, Jorge
BLOOD, 2007, 110 (11) : 573A - 573A
[30] Long-term outcome of tyrosine kinase inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase
Yong-Zhi Zheng
Jian Li
Cai Chen
Hao Zheng
Dan-Hui Fu
Jian-Da Hu
中华医学杂志(英文版), 2021, 134 (24) : 3009 - 3011

← 1 2 3 4 5 →